Aberrant reward processing in Parkinson's disease is associated with dopamine cell loss

NeuroImage

Volumn 59, Issue 4, 2012, Pages 3339-3346

  Aarts, Esther ^a,b   Helmich, Rick C ^a,b   Janssen, Marcel J R ^a,b   Oyen, Wim J G ^a,b   Bloem, Bastiaan R ^a,b   Cools, Roshan ^a,b  

^a RADBOUD UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dopamine; Flexibility; Impulsivity; Parkinson's disease; Reward; SPECT

Indexed keywords

DOPAMINE TRANSPORTER;

ADULT; AGED; ARTICLE; CELL LOSS; CLINICAL ARTICLE; COGNITION; COGNITIVE INFLEXIBILITY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE CELL LOSS; FEMALE; HUMAN; IMPULSIVENESS; MALE; NEUROIMAGING; PARKINSON DISEASE; POSTERIOR PUTAMEN; PRIORITY JOURNAL; RESPONSE TIME; REWARD; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TASK PERFORMANCE;

DOPAMINE; FEMALE; HUMANS; IMPULSIVE BEHAVIOR; MALE; MIDDLE AGED; PARKINSON DISEASE; REWARD; TASK PERFORMANCE AND ANALYSIS;

EID: 84855164495     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2011.11.073     Document Type: Article

References (59)

1. Aarts E., Roelofs A., Franke B., Rijpkema M., Fernandez G., Helmich R.C., Cools R. Striatal dopamine mediates the interface between motivational and cognitive control in humans: evidence from genetic imaging. Neuropsychopharmacology 2010, 35:1943-1951.
2. Aarts E., Van Holstein M., Cools R. Striatal dopamine and the interface between motivation and cognition. Front. Psychol. 2011.
3. Blum K., Braverman E.R., Holder J.M., Lubar J.F., Monastra V.J., Miller D., Lubar J.O., Chen T.J., Comings D.E. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J. Psychoactive Drugs 2000, 32(Suppl, i-iv):1-112.
4. Boileau I., Dagher A., Leyton M., Gunn R.N., Baker G.B., Diksic M., Benkelfat C. Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. Arch. Gen. Psychiatry 2006, 63:1386-1395.
5. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
6. Brooks D.J., Piccini P. Imaging in Parkinson's disease: the role of monoamines in behavior. Biol. Psychiatry 2006, 59:908-918.
7. Buckholtz J.W., Treadway M.T., Cowan R.L., Woodward N.D., Li R., Ansari M.S., Baldwin R.M., Schwartzman A.N., Shelby E.S., Smith C.E., Kessler R.M., Zald D.H. Dopaminergic network differences in human impulsivity. Science 2010, 329:532.
8. Carver C.S., White T.L. Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment: the BIS/BAS scales. J. Personal. Soc. Psychol. 1994, 67:319-333.
9. Comings D.E., Blum K. Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog. Brain Res. 2000, 126:325-341.
10. Cools R. Dopaminergic modulation of cognitive function-implications for l-DOPA treatment in Parkinson's disease. Neurosci. Biobehav. Rev. 2006, 30:1-23.
11. Cools R., Barker R.A., Sahakian B.J., Robbins T.W. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb. Cortex 2001, 11:1136-1143.
12. Cools R., Barker R.A., Sahakian B.J., Robbins T.W. Mechanisms of cognitive set flexibility in Parkinson's disease. Brain 2001, 124:2503-2512.
13. Cools R., Barker R.A., Sahakian B.J., Robbins T.W. l-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia 2003, 41:1431-1441.
14. Cools R., Altamirano L., D'Esposito M. Reversal learning in Parkinson's disease depends on medication status and outcome valence. Neuropsychologia 2006, 44:1663-1673.
15. Cools R., Lewis S.J., Clark L., Barker R.A., Robbins T.W. l-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology 2007, 32:180-189.
16. Cools R., Sheridan M., Jacobs E., D'Esposito M. Impulsive personality predicts dopamine-dependent changes in frontostriatal activity during component processes of working memory. J. Neurosci. 2007, 27:5506-5514.
17. Dagher A., Robbins T.W. Personality, addiction, dopamine: insights from Parkinson's disease. Neuron 2009, 61:502-510.
18. Dalley J.W., Fryer T.D., Brichard L., Robinson E.S., Theobald D.E., Laane K., Pena Y., Murphy E.R., Shah Y., Probst K., Abakumova I., Aigbirhio F.I., Richards H.K., Hong Y., Baron J.C., Everitt B.J., Robbins T.W. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 2007, 315:1267-1270.
19. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:5274-5278.
20. Dubois B., Slachevsky A., Litvan I., Pillon B. The FAB: a frontal assessment battery at bedside. Neurology 2000, 55:1621-1626.
21. Evans A.H., Pavese N., Lawrence A.D., Tai Y.F., Appel S., Doder M., Brooks D.J., Lees A.J., Piccini P. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann. Neurol. 2006, 59:852-858.
22. Evans A.H., Strafella A.P., Weintraub D., Stacy M. Impulsive and compulsive behaviors in Parkinson's disease. Mov. Disord. 2009, 24:1561-1570.
23. Frank M.J., Seeberger L.C., O'Reilly R.C. By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science 2004, 306:1940-1943.
24. Frank M.J., Samanta J., Moustafa A.A., Sherman S.J. Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism. Science 2007, 318:1309-1312.
25. Franken I.H.A., Muris P., Rassin E. Psychometric properties of the Dutch BIS/BAS scales. J. Psychopathol. Behav. Assess. 2005, 27:25-30.
26. Gallagher D.A., O'Sullivan S.S., Evans A.H., Lees A.J., Schrag A. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov. Disord. 2007, 22:1757-1763.
27. Hazy T.E., Frank M.J., O'Reilly R.C. Banishing the homunculus: making working memory work. Neuroscience 2006, 139:105-118.
28. Helmich R.C., Derikx L.C., Bakker M., Scheeringa R., Bloem B.R., Toni I. Spatial remapping of cortico-striatal connectivity in Parkinson's disease. Cereb. Cortex 2010, 20:1175-1186.
29. Hinson J.M., Jameson T.L., Whitney P. Impulsive decision making and working memory. J. Exp. Psychol. Learn. Mem. Cogn. 2003, 29:298-306.
30. Housden C.R., O'Sullivan S.S., Joyce E.M., Lees A.J., Roiser J.P. Intact reward learning but elevated delay discounting in Parkinson's disease patients with impulsive-compulsive spectrum behaviors. Neuropsychopharmacology 2010, 35:2155-2164.
31. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 1988, 318:876-880.
32. Lehericy S., Benali H., Van de Moortele P.F., Pelegrini-Issac M., Waechter T., Ugurbil K., Doyon J. Distinct basal ganglia territories are engaged in early and advanced motor sequence learning. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:12566-12571.
33. Lewis S., Slabosz A., Robbins T.W., Barker R.A., Owen A.M. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease. Neuropsychologia 2005, 43:823-832.
34. Leyton M., Boileau I., Benkelfat C., Diksic M., Baker G., Dagher A. Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: a PET/[11C]raclopride study in healthy men. Neuropsychopharmacology 2002, 27:1027-1035.
35. Lott D.C., Kim S.J., Cook E.H., de Wit H. Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology 2005, 30:602-609.
36. Nader M.A., Morgan D., Gage H.D., Nader S.H., Calhoun T.L., Buchheimer N., Ehrenkaufer R., Mach R.H. PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nat. Neurosci. 2006, 9:1050-1056.
37. O'Sullivan S.S., Wu K., Politis M., Lawrence A.D., Evans A.H., Bose S.K., Djamshidian A., Lees A.J., Piccini P. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain 2011, 134:969-978.
38. Patenaude B., Smith S.M., Kennedy D.N., Jenkinson M. A Bayesian model of shape and appearance for subcortical brain segmentation. NeuroImage 2011, 56:907-922.
39. Peters J., Buchel C. The neural mechanisms of inter-temporal decision-making: understanding variability. Trends Cogn. Sci. 2011, 15:227-239.
40. Pontone G., Williams J.R., Bassett S.S., Marsh L. Clinical features associated with impulse control disorders in Parkinson disease. Neurology 2006, 67:1258-1261.
41. Postuma R.B., Dagher A. Basal ganglia functional connectivity based on a meta-analysis of 126 positron emission tomography and functional magnetic resonance imaging publications. Cereb. Cortex 2006, 16:1508-1521.
42. Reuter J., Raedler T., Rose M., Hand I., Glascher J., Buchel C. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat. Neurosci. 2005, 8:147-148.
43. Rutledge R.B., Lazzaro S.C., Lau B., Myers C.E., Gluck M.A., Glimcher P.W. Dopaminergic drugs modulate learning rates and perseveration in Parkinson's patients in a dynamic foraging task. J. Neurosci. 2009, 29:15104-15114.
44. Scherfler C., Seppi K., Donnemiller E., Goebel G., Brenneis C., Virgolini I., Wenning G.K., Poewe W. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain 2005, 128:1605-1612.
45. Shahmoradgoli Najafabadi M., Ohadi M., Joghataie M.T., Valaie F., Riazalhosseini Y., Mostafavi H., Mohammadbeigi F., Najmabadi H. Association between the DRD2 A1 allele and opium addiction in the Iranian population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 134B:39-41.
46. Shamosh N.A., Deyoung C.G., Green A.E., Reis D.L., Johnson M.R., Conway A.R., Engle R.W., Braver T.S., Gray J.R. Individual differences in delay discounting: relation to intelligence, working memory, and anterior prefrontal cortex. Psychol. Sci. 2008, 19:904-911.
47. Sheskin D.J. The Handbook of Parametric and Nonparametric Statistical Procedures 2003, Chapman & Hall/CRC, Boca Raton, FL. 3 ed.
48. Shohamy D., Myers C.E., Geghman K.D., Sage J., Gluck M.A. l-dopa impairs learning, but spares generalization, in Parkinson's disease. Neuropsychologia 2006, 44:774-784.
49. Slabosz A., Lewis S.J., Smigasiewicz K., Szymura B., Barker R.A., Owen A.M. The role of learned irrelevance in attentional set-shifting impairments in Parkinson's disease. Neuropsychology 2006, 20:578-588.
50. Spiegel J., Hellwig D., Samnick S., Jost W., Mollers M.O., Fassbender K., Kirsch C.M., Dillmann U. Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease. J. Neural. Transm. 2007, 114:331-335.
51. Spreckelmeyer K.N., Krach S., Kohls G., Rademacher L., Irmak A., Konrad K., Kircher T., Grunder G. Anticipation of monetary and social reward differently activates mesolimbic brain structures in men and women. Soc. Cogn. Affect. Neurosci. 2009, 4:158-165.
52. Steeves T.D., Miyasaki J., Zurowski M., Lang A.E., Pellecchia G., Van Eimeren T., Rusjan P., Houle S., Strafella A.P. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009, 132:1376-1385.
53. Swainson R., Rogers R.D., Sahakian B.J., Summers B.A., Polkey C.E., Robbins T.W. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia 2000, 38:596-612.
54. Thobois S., Vingerhoets F., Fraix V., Xie-Brustolin J., Mollion H., Costes N., Mertens P., Benabid A.L., Pollak P., Broussolle E. Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study. Arch. Neurol. 2004, 61:1705-1709.
55. van Oosten R.V., Verheij M.M., Cools A.R. Bilateral nigral 6-hydroxydopamine lesions increase the amount of extracellular dopamine in the nucleus accumbens. Exp. Neurol. 2005, 191:24-32.
56. Voon V., Sohr M., Lang A.E., Potenza M.N., Siderowf A.D., Whetteckey J., Weintraub D., Wunderlich G.R., Stacy M. Impulse control disorders in Parkinson disease: a multicenter case-control study. Ann. Neurol. 2011.
57. Weintraub D., Koester J., Potenza M.N., Siderowf A.D., Stacy M., Voon V., Whetteckey J., Wunderlich G.R., Lang A.E. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch. Neurol. 2010, 67:589-595.
58. Wenzelburger R., Zhang B.R., Pohle S., Klebe S., Lorenz D., Herzog J., Wilms H., Deuschl G., Krack P. Force overflow and levodopa-induced dyskinesias in Parkinson's disease. Brain 2002, 125:871-879.
59. Wylie G., Allport A. Task switching and the measurement of "switch costs". Psychol. Res. 2000, 63:212-233.